Tetra-PEG hydrogels based on the ammonolysis reaction between tetra-armed poly(ethylene glycol) amine (Tetra-PEG-NH2) and Tetra-PEG-SAE offer massive advantages as sealants. They are entirely synthetic without the misgivings of being inhibited by anticoagulation agents and transferring disease. Their cost is low due to their easily preservable components with high accessibility. Because of the intrinsic properties of this ammonolysis reaction, the resulting hydrogels can gel  fast just by injection and adhere to the tissues tightly throughchemical bonds. Another remarkable advantage for Tetra-PEG hydrogels is that they are mechanically tough, and the sealants are favored to be mechanically tough to keep stable in case of dynamic movement of the tissues and the use of assistant pressure which is a key adjunctive step in achieving hemostasis. However, two hurdles are preventing extending their applications in vivo. The first one is that just as commercialized sealants, none of the reported Tetra-PEG hydrogels could be controllably removed without mechanical debridement, which is extremely dangerous because of their high mechanical strength. Besides, they possess long degradation time, which will lead to severe foreign body reactions, tissue adhesion, disturbed tissue healing, and obstruction of the circulatory system, when used in vivo. Here, to overcome the limitations of the existing ammonolysis based Tetra-PEG hydrogels, we construct an optimized one (SS) with fast degradable and controllably dissolvable properties via Tetra-PEG-NH2 and tetra-armed poly(ethylene glycol) succinimidyl succinate (Tetra-PEG-SS) . The resulting SS exhibits biocompatibility superior to the reported degradable Tetra-PEG hydrogel (SG) based on Tetra-PEG-NH2 and tetra-armed poly(ethylene glycol) succinimidyl glutarate (Tetra-PEG-SG) . More importantly, in contrast to the disappointing results of SG that leads to serious adverse effects in in vivo hemostasis due to the long retention, SS causes almost no noticeable side effects with outstanding hemostasis efficacy even under the anticoagulated situations. This hydrogel is a promising candidate for the next-generation in vivo sealants in the aged society.

CPhI China 2019 was held successfully in Shanghai, China from June 18th-20th. We Sinopeg sent a very professional sales team to participate this exhibition. Our booth Number is W4F21. During the exhibition, we had very deep disscuion with old partner, and customers from all over the world came to  consult the company's products，we obtained the approval and praise from our customers. Looking forward to see you again next year, CPhI China 2020 in Shanghai.

Warmly welcome you to visit our booth 1D73 in API  (Hangzhou) from May. 8th to May. 10th, 2019. Exhibition name: the 82nd API China- China international pharmaceutical raw materials, intermediates, packaging, equipment fair. Booth number:1D73 Time: May 8-10,2019 Venue: Hangzhou international expo center We provided a wealth of polyethylene glycol derivatives, side chains of hypoglycemic drugs (Semaglutide side chain, Liraglutide side chain, Insulin Detemir side chain, Insulin Deglutide chain), polyethylene glycol block copolymers, polyethylene glycol phospholipids, etc. Welcome to our booth.

Welcome to visit us at

The first half of 2025 saw sinopeg set sail once more, actively engaging on the global frontier of pharmaceuticals and advanced delivery technologies. With cutting-edge solutions and an open collaborative spirit, we showcased our innovation at two premier industry events in the U.S., gaining invaluable industry insights and forging broad partnership opportunities. Now, let’s revisit this remarkable journey and extend a heartfelt invitation to global partners! First Stop: TIDES USA 2025 (San Diego, USA | May 19–22) As a premier global summit for oligonucleotides, peptides, mRNA, and gene editing, TIDES USA 2025 gathered industry leaders in May. The Sinopeg team immersed in deep dialogues with global R&D scientists and technical experts on trending topics, demonstrating our expertise and one-stop solution capabilities in these fields. We connected with numerous new partners at TIDES USA, laying a solid foundation for future collaborations. Second Stop: Extra-Hepatic Lipid-Based Nanoparticle Delivery Summit (Boston, USA | June 24–26) — Exclusive Sponsor: sinopeg! In late June, Boston hosted a landmark summit focused on extra-hepatic targeted lipid nanoparticle (LNP) delivery technology. Sinopeg was honored to serve as the Exclusive Sponsor! This not only highlighted our leadership in LNP delivery but also created a unique platform for deep engagement. Leveraging our exclusive sponsorship, we held intensive and productive discussions with a vast number of attendees from top global pharma companies and academic institutions. These dynamic exchanges sparked intellectual synergies and explored concrete collaboration opportunities, exceeding all expectations! Autumn in Europe: See You Again! Our successful H1 ventures have equipped us with invaluable experience and reinforced our confidence. Sinopeg’s commitment to global expansion continues! In the second half of 2025, we will return to two key European exhibitions: 1.CPhI Worldwide 2025 (Frankfurt, Germany | October 28–30) The world’s premier pharmaceutical event covering APIs, formulations, biopharma, and outsourcing services across the entire supply chain. Visit us at Booth 8.0T48 to explore our comprehensive technical capabilities and global services! 2.TIDES Europe 2025 (Switzerland | November 11–13) Europe’s leading conference for oligonucleotide and peptide therapies, driving innovation from discovery to commercialization. Join us at Booth 333 to discuss collaboration and breakthroughs! We cordially invite all partners worldwide: Whether you seek to explore our technology platforms or discuss frontier project collaborations, visit sinopeg’s booths at the above events! This autumn, Europe awaits! Thesinopeg team is ready to meet you face-to-face in Frankfurt and Switzerland. Together, let’s shape the industry’s future and pioneer new partnerships — empowering drug development with innovation to bring more hope to patients worldwide!

Product Name: XcellFect RNA Transfection Reagent Catalog No.: D7010101 Storage: Sealed at 4°C. Avoid repeated freeze-thaw cycles. Why Choose XcellFect? High Efficiency, Low Toxicity: Powered by our patented lipid-based formulation, XcellFect overcomes traditional delivery bottlenecks to deliver ultra-high transfection efficiency while maintaining minimal cytotoxicity. Say goodbye to compromised cell viability! Broad Spectrum Compatibility: Designed for versatility, XcellFect works seamlessly across common cell lines and is specially optimized for hard-to-transfect cells. No more struggling with inconsistent results! Multi-RNA Flexibility: Whether you’re working with siRNA, mRNA, miRNA, or other RNA types, XcellFect ensures robust delivery for diverse applications—from gene silencing to therapeutic development. Streamlined Workflow: Just mix Reagent A and B, combine with RNA, and add to cells—no media replacement needed! Compatible with complete culture media, saving you time and simplifying protocols. Ideal For: Gene function studies Therapeutic RNA delivery CRISPR-Cas9 workflows High-throughput screening ransform Your Research Today! contact our team at polydarwin@sinopeg.com to learn more or request a sample. Let XcellFect accelerate your breakthroughs in RNA-based science!